Helena R Chang

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 3

Top Topics

Locally Advanced

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Ann M Chan, Brian Aguirre, Lucia Liu, Vei Mah, Justin M Balko, Jessica Tsui, Navin P Wadehra, Neda A Moatamed, Mahdi Khoshchehreh, Christen M Dillard, Meagan Kiyohara, Yahya Elshimali, Helena R Chang, Diana C Marquez-Garban, Nalo Hamilton, Richard J Pietras, Lynn K Gordon, Madhuri Wadehra
EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancers 16 (8) (2024)
Ann M Chan, Brian Aguirre, Lucia Liu, Vei Mah, Justin M Balko, Jessica Tsui, Navin P Wadehra, Neda A Moatamed, Mahdi Khoshchehreh, Christen M Dillard, Meagan Kiyohara, Yahya Elshimali, Helena R Chang, Diana C Marquez-Garban, Nalo Hamilton, Richard J Pietras, Lynn K Gordon, Madhuri Wadehra
EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancers 16 (8) (2024)
Vina P Nguyen, Katie M Campbell, Theodore Scott Nowicki, Nila Elumalai, Egmidio Medina, Ignacio Baselga Carretero, Maggie L DiNome, Helena R Chang, Denise K Oseguera, Antoni Ribas, John A Glaspy
A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer. Cancer research communications 3 (8) (2023)